Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Metastatic or Advanced Solid Tumors (MAST).

NCT05346484 is registered in ClinicalTrials.gov with Imugene Limited as lead sponsor.

NCT NCT05346484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05346484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Metastatic or Advanced Solid Tumors (MAST).
Lead sponsor
Imugene Limited
Phase
Phase 1
Overall status
Terminated
Start date
May 17, 2022
Completion date
January 12, 2026
Enrollment
66 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, bile duct cancer, cholangiocarcinoma, metastatic cancer, solid carcinoma, solid tumor, solid tumor, adult